You are here

  • Home
  • Archive
  • Volume 70, Issue 6
  • Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Strand V, Smolen JS, van Vollenhoven RF, et al
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
Annals of the Rheumatic Diseases 2011;70:996-1002.